Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with
surgical resection of the primary tumour and systemic chemotherapy, which provides …

Mortality from pancreatic ductal adenocarcinoma (PDAC) is increasing worldwide and
effective new treatments are urgently needed. The current treatment of metastatic PDAC in fit …

The management of pancreatic ductal adenocarcinoma (PDAC) has posed a considerable
challenge for decades, with incidence and mortality rates almost mirroring each other …

Background KRAS mutation is the most common molecular alteration in pancreatic
adenocarcinoma (PDAC), and around 10% of patients harbor KRAS wild-type tumors (KRAS …

Gastrointestinal (GI) malignancies encompass a broad range of tumors with limited
treatment options, particularly for advanced disease. With the development and …

Introduction Prognosis of patients with metastatic pancreatic ductal adenocarcinoma
(mPDAC) remains disappointing with a 5-year overall survival of only 3–5%. Compared to …

Gene fusions and rearrangements play a crucial role in tumor biology. They are rare events
typically detected in KRAS wild-type (WT) pancreatic tumors. Their identification can inform …

Pancreatic adenocarcinoma (PDAC) is predicted to become the second leading cause of
cancer deaths by 2030 and this is mostly due to therapy failure. Limited treatment options …

BRAF-altered pancreatic cancer is an important molecular subgroup that activates the
mitogen-activated protein kinase pathway and promotes tumorigenesis. This manuscript …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) has a notoriously bad
prognosis due to its high mortality and lack of good therapies. Chemotherapy is the current …